Reardon Andrew, CLO and Secretary of Ligand Pharmaceuticals ($LGND), sold shares on the open market fourteen times over the last year, totaling $1.25 million. His most recent sale occurred on March 4, 2026. These sales rank 4,421st among 11,678 individual insiders in our database, where the average is $8.6 million across about 6.4 transactions. Reardon Andrew made no open market purchases in the period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| April 1, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Reardon Andrew | CLO & Secretary | S | Common Stock | 337 | $204.50 | 41,382.0000 | 20,629,000 | 0.81% | 0.00% |
| April 1, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Reardon Andrew | CLO & Secretary | S | Common Stock | 700 | $201.90 | 42,682.0000 | 20,629,000 | 1.61% | 0.00% |
| April 1, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Reardon Andrew | CLO & Secretary | S | Common Stock | 1238 | $200.94 | 43,382.0000 | 20,629,000 | 2.77% | 0.01% |
| April 1, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Reardon Andrew | CLO & Secretary | S | Common Stock | 1302 | $199.72 | 44,620.0000 | 20,629,000 | 2.84% | 0.01% |
| April 1, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Reardon Andrew | CLO & Secretary | S | Common Stock | 460 | $198.85 | 45,922.0000 | 20,629,000 | 0.99% | 0.00% |
| April 1, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Reardon Andrew | CLO & Secretary | M | Common Stock | 5000 | $52.27 | 46,382.0000 | 20,629,000 | 12.08% | 0.02% |
| April 1, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Reardon Andrew | CLO & Secretary | M | Employee Stock Option (right to buy) | 5000 | $0.00 | 49,444.0000 | 20,629,000 | 9.18% | 0.02% |
| April 1, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Reardon Andrew | CLO & Secretary | S | Common Stock | 963 | $203.22 | 41,719.0000 | 20,629,000 | 2.26% | 0.00% |
| March 2, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Reardon Andrew | CLO & Secretary | A | Employee Stock Option (right to buy) | 21525 | $0.00 | 21,525.0000 | 20,629,000 | 9999.99% | 0.10% |
| March 2, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Reardon Andrew | CLO & Secretary | A | Common Stock | 4513 | $0.00 | 41,382.0000 | 20,629,000 | 12.24% | 0.02% |
| March 4, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Reardon Andrew | CLO & Secretary | S | Common Stock | 207 | $199.96 | 41,462.0000 | 20,629,000 | 0.50% | 0.00% |
| March 4, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Reardon Andrew | CLO & Secretary | S | Common Stock | 100 | $199.01 | 41,669.0000 | 20,629,000 | 0.24% | 0.00% |
| March 4, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Reardon Andrew | CLO & Secretary | M | Common Stock | 5000 | $52.27 | 41,869.0000 | 20,629,000 | 13.56% | 0.02% |
| March 4, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Reardon Andrew | CLO & Secretary | S | Common Stock | 100 | $197.70 | 41,769.0000 | 20,629,000 | 0.24% | 0.00% |
| March 4, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Reardon Andrew | CLO & Secretary | M | Employee Stock Option (right to buy) | 5000 | $0.00 | 54,444.0000 | 20,629,000 | 8.41% | 0.02% |
| March 4, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Reardon Andrew | CLO & Secretary | S | Common Stock | 1142 | $208.87 | 36,869.0000 | 20,629,000 | 3.00% | 0.01% |
| March 4, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Reardon Andrew | CLO & Secretary | S | Common Stock | 1446 | $208.12 | 38,011.0000 | 20,629,000 | 3.66% | 0.01% |
| March 4, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Reardon Andrew | CLO & Secretary | S | Common Stock | 612 | $207.01 | 39,457.0000 | 20,629,000 | 1.53% | 0.00% |
| March 4, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Reardon Andrew | CLO & Secretary | S | Common Stock | 340 | $206.37 | 40,069.0000 | 20,629,000 | 0.84% | 0.00% |
| March 4, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Reardon Andrew | CLO & Secretary | S | Common Stock | 460 | $205.18 | 40,409.0000 | 20,629,000 | 1.13% | 0.00% |
| March 4, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Reardon Andrew | CLO & Secretary | S | Common Stock | 200 | $204.17 | 40,869.0000 | 20,629,000 | 0.49% | 0.00% |
| March 4, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Reardon Andrew | CLO & Secretary | S | Common Stock | 300 | $201.70 | 41,069.0000 | 20,629,000 | 0.73% | 0.00% |
| March 4, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Reardon Andrew | CLO & Secretary | S | Common Stock | 93 | $200.62 | 41,369.0000 | 20,629,000 | 0.22% | 0.00% |
| Feb. 14, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Reardon Andrew | CLO & Secretary | F | Common Stock | 3211 | $183.83 | 34,528.0000 | 20,629,000 | 8.51% | 0.02% |
| Feb. 14, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Reardon Andrew | CLO & Secretary | A | Common Stock | 6928 | $0.00 | 37,739.0000 | 20,629,000 | 22.49% | 0.03% |
| Feb. 14, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Reardon Andrew | CLO & Secretary | A | Common Stock | 8810 | $0.00 | 43,338.0000 | 20,629,000 | 25.52% | 0.04% |
| Feb. 14, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Reardon Andrew | CLO & Secretary | F | Common Stock | 4083 | $183.83 | 39,255.0000 | 20,629,000 | 9.42% | 0.02% |
| Feb. 15, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Reardon Andrew | CLO & Secretary | F | Common Stock | 593 | $183.83 | 38,662.0000 | 20,629,000 | 1.51% | 0.00% |
| Feb. 15, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Reardon Andrew | CLO & Secretary | F | Common Stock | 801 | $183.83 | 37,861.0000 | 20,629,000 | 2.07% | 0.00% |
| Feb. 15, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Reardon Andrew | CLO & Secretary | F | Common Stock | 992 | $183.83 | 36,869.0000 | 20,629,000 | 2.62% | 0.00% |
| Aug. 10, 2025 | LIGAND PHARMACEUTICALS INC | $LGND | Reardon Andrew | CLO & Secretary | F | Common Stock | 1325 | $150.06 | 30,811.0000 | 18,290,000 | 4.12% | 0.01% |
| June 30, 2025 | LIGAND PHARMACEUTICALS INC | $LGND | Reardon Andrew | CLO & Secretary | J | Common Stock | 233 | $91.08 | 32,136.0000 | 18,290,000 | 0.73% | 0.00% |
| June 23, 2025 | LIGAND PHARMACEUTICALS INC | $LGND | Reardon Andrew | CLO & Secretary | S | Common Stock | 500 | $114.08 | 31,903.0000 | 18,290,000 | 1.54% | 0.00% |
| June 10, 2025 | LIGAND PHARMACEUTICALS INC | $LGND | Reardon Andrew | CLO & Secretary | S | Common Stock | 500 | $114.54 | 32,403.0000 | 18,290,000 | 1.52% | 0.00% |
| May 15, 2025 | LIGAND PHARMACEUTICALS INC | $LGND | Reardon Andrew | CLO & Secretary | S | Common Stock | 1000 | $104.00 | 32,903.0000 | 18,290,000 | 2.95% | 0.01% |
| Aug. 10, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Reardon Andrew | CLO & Secretary | F | Common Stock | 897 | $100.16 | 21,637.0000 | 17,757,000 | 3.98% | 0.01% |
| March 4, 2025 | LIGAND PHARMACEUTICALS INC | $LGND | Reardon Andrew | CLO & Secretary | A | Employee Stock Option (right to buy) | 28043 | $0.00 | 28,043.0000 | 18,290,000 | 9999.99% | 0.15% |
| March 4, 2025 | LIGAND PHARMACEUTICALS INC | $LGND | Reardon Andrew | CLO & Secretary | A | Common Stock | 6415 | $0.00 | 34,783.0000 | 18,290,000 | 22.61% | 0.04% |
| Feb. 14, 2025 | LIGAND PHARMACEUTICALS INC | $LGND | Reardon Andrew | CLO & Secretary | A | Common Stock | 6928 | $0.00 | 29,462.0000 | 18,290,000 | 30.74% | 0.04% |
| Feb. 15, 2025 | LIGAND PHARMACEUTICALS INC | $LGND | Reardon Andrew | CLO & Secretary | F | Common Stock | 876 | $120.00 | 28,368.0000 | 18,290,000 | 3.00% | 0.00% |
| Feb. 15, 2025 | LIGAND PHARMACEUTICALS INC | $LGND | Reardon Andrew | CLO & Secretary | F | Common Stock | 1114 | $120.00 | 29,244.0000 | 18,290,000 | 3.67% | 0.01% |
| Feb. 14, 2025 | LIGAND PHARMACEUTICALS INC | $LGND | Reardon Andrew | CLO & Secretary | F | Common Stock | 1758 | $120.00 | 30,358.0000 | 18,290,000 | 5.47% | 0.01% |
| Feb. 14, 2025 | LIGAND PHARMACEUTICALS INC | $LGND | Reardon Andrew | CLO & Secretary | A | Common Stock | 5429 | $0.00 | 32,116.0000 | 18,290,000 | 20.34% | 0.03% |
| Feb. 14, 2025 | LIGAND PHARMACEUTICALS INC | $LGND | Reardon Andrew | CLO & Secretary | F | Common Stock | 2775 | $120.00 | 26,687.0000 | 18,290,000 | 9.42% | 0.02% |
| Sept. 23, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Reardon Andrew | CLO & Secretary | M | Common Stock | 2000 | $52.27 | 24,534.0000 | 17,757,000 | 8.88% | 0.01% |
| Sept. 23, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Reardon Andrew | CLO & Secretary | S | Common Stock | 2000 | $99.60 | 22,534.0000 | 17,757,000 | 8.15% | 0.01% |
| Sept. 23, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Reardon Andrew | CLO & Secretary | M | Employee Stock Option (right to buy) | 2000 | $0.00 | 70,944.0000 | 17,757,000 | 2.74% | 0.01% |
| Aug. 28, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Reardon Andrew | CLO & Secretary | S | Common Stock | 1500 | $106.39 | 22,534.0000 | 17,757,000 | 6.24% | 0.01% |
| Aug. 28, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Reardon Andrew | CLO & Secretary | M | Non-Qualified Stock Option (right to buy) | 1500 | $0.00 | 61,444.0000 | 17,757,000 | 2.38% | 0.01% |
| Aug. 28, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Reardon Andrew | CLO & Secretary | M | Common Stock | 1500 | $52.27 | 24,034.0000 | 17,757,000 | 6.66% | 0.01% |
| June 28, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Reardon Andrew | Chief Legal Officer & | J | Common Stock | 329 | $60.71 | 22,534.0000 | 17,757,000 | 1.48% | 0.00% |
| May 9, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Reardon Andrew | Chief Legal Officer & | M | Non-Qualified Stock Option (right to buy) | 10000 | $0.00 | 62,944.0000 | 17,757,000 | 13.71% | 0.06% |
| May 9, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Reardon Andrew | Chief Legal Officer & | M | Common Stock | 10000 | $52.27 | 32,205.0000 | 17,757,000 | 45.03% | 0.06% |
| May 9, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Reardon Andrew | Chief Legal Officer & | S | Common Stock | 10000 | $83.04 | 22,205.0000 | 17,757,000 | 31.05% | 0.06% |
| Feb. 27, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Reardon Andrew | CHIEF LEGAL OFFICER & | A | Common Stock | 7208 | $0.00 | 22,205.0000 | 17,757,000 | 48.06% | 0.04% |
| Feb. 27, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Reardon Andrew | CHIEF LEGAL OFFICER & | A | Employee Stock Option (right to buy) | 29272 | $0.00 | 29,272.0000 | 17,757,000 | 9999.99% | 0.16% |
| Feb. 15, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Reardon Andrew | CHIEF LEGAL OFFICER & | F | Common Stock | 593 | $74.65 | 14,997.0000 | 17,757,000 | 3.80% | 0.00% |
| Dec. 29, 2023 | LIGAND PHARMACEUTICALS INC | $LGND | Reardon Andrew | CHIEF LEGAL OFFICER & | J | Common Stock | 179 | $60.71 | 15,590.0000 | 16,868,000 | 1.16% | 0.00% |